Literature DB >> 22085888

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.

Jos Prickaerts1, Nick P van Goethem, Richard Chesworth, Gideon Shapiro, Frank G Boess, Christoph Methfessel, Olga A H Reneerkens, Dorothy G Flood, Dana Hilt, Maria Gawryl, Sonia Bertrand, Daniel Bertrand, Gerhard König.   

Abstract

EVP-6124, (R)-7-chloro-N-quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs) that was evaluated here in vitro and in vivo. In binding and functional experiments, EVP-6124 showed selectivity for α7 nAChRs and did not activate or inhibit heteromeric α4β2 nAChRs. EVP-6124 had good brain penetration and an adequate exposure time. EVP-6124 (0.3 mg/kg, p.o.) significantly restored memory function in scopolamine-treated rats (0.1 mg/kg, i.p.) in an object recognition task (ORT). Although donepezil at 0.1 mg/kg, p.o. or EVP-6124 at 0.03 mg/kg, p.o. did not improve memory in this task, co-administration of these sub-efficacious doses fully restored memory. In a natural forgetting test, an ORT with a 24 h retention time, EVP-6124 improved memory at 0.3 mg/kg, p.o. This improvement was blocked by the selective α7 nAChR antagonist methyllycaconitine (0.3 mg/kg, i.p. or 10 μg, i.c.v.). In co-application experiments of EVP-6124 with acetylcholine, sustained exposure to EVP-6124 in functional investigations in oocytes caused desensitization at concentrations greater than 3 nM, while lower concentrations (0.3-1 nM) caused an increase in the acetylcholine-evoked response. These actions were interpreted as representing a co-agonist activity of EVP-6124 with acetylcholine on α7 nAChRs. The concentrations of EVP-6124 that resulted in physiological potentiation were consistent with the free drug concentrations in brain that improved memory performance in the ORT. These data suggest that the selective partial agonist EVP-6124 improves memory performance by potentiating the acetylcholine response of α7 nAChRs and support new therapeutic strategies for the treatment of cognitive impairment. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22085888     DOI: 10.1016/j.neuropharm.2011.10.024

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  64 in total

Review 1.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

2.  Discovery of an intrasubunit nicotinic acetylcholine receptor-binding site for the positive allosteric modulator Br-PBTC.

Authors:  Jack Norleans; Jingyi Wang; Alexander Kuryatov; Abba Leffler; Christelle Doebelin; Theodore M Kamenecka; Jon Lindstrom
Journal:  J Biol Chem       Date:  2019-06-20       Impact factor: 5.157

Review 3.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

4.  The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.

Authors:  Patricia Spilman; Olivier Descamps; Olivia Gorostiza; Clare Peters-Libeu; Karen S Poksay; Alexander Matalis; Jesus Campagna; Alexander Patent; Rammohan Rao; Varghese John; Dale E Bredesen
Journal:  Brain Res       Date:  2013-12-31       Impact factor: 3.252

5.  Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant β Subunits Acquire Sensitivity to α7-Selective Positive Allosteric Modulators.

Authors:  Clare Stokes; Sumanta Garai; Abhijit R Kulkarni; Lucas N Cantwell; Colleen M Noviello; Ryan E Hibbs; Nicole A Horenstein; Khalil A Abboud; Ganesh A Thakur; Roger L Papke
Journal:  J Pharmacol Exp Ther       Date:  2019-06-07       Impact factor: 4.030

6.  AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.

Authors:  Dominik Feuerbach; Nicole Pezous; Markus Weiss; Kasra Shakeri-Nejad; Kurt Lingenhoehl; Daniel Hoyer; Konstanze Hurth; Graeme Bilbe; Christopher R Pryce; Kevin McAllister; Frederique Chaperon; Klaus Kucher; Donald Johns; Thomas Blaettler; Cristina Lopez Lopez
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

7.  Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects.

Authors:  Paul A Newhouse
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

Review 8.  Alzheimer's Disease Therapeutic Approaches.

Authors:  Maria Revi
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.

Authors:  Mei Huang; Anna R Felix; Dorothy G Flood; Chaya Bhuvaneswaran; Dana Hilt; Gerhard Koenig; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

10.  Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Authors:  Frank G Boess; Jean de Vry; Christina Erb; Timo Flessner; Martin Hendrix; Joachim Luithle; Christoph Methfessel; Katrin Schnizler; F Josef van der Staay; Marja van Kampen; Welf-Burkhard Wiese; Gerhard König
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.